• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Noble’s AdhereIT® Provides Flexibility of Design, Empowers Patients and Encourages Adherence

August 1, 2022 By Sponsored Content

A recent study1 commissioned by Noble International analyzed the biologic initiation process and current gaps pertaining to patient guidance and self-injection training practices. Anecdotal evidence showed that more than one-third of participating patients lacked the necessary confidence to self-inject during their first six months of treatment due to inadequate training practices. The study further maintained that considerable attention must be paid to providing patients with multiple opportunities for training—be it through practice sessions, training devices or at-home access to further medical information.

Here at Noble, we have made it our mission to help our clients in the pharmaceutical industry provide innovative products and services; we strive to provide patients with the resources and support needed to help them achieve better health outcomes.

However, if patients are to become and stay adherent to their self-injection regimen, then they must be given the tools they need to succeed.

Robust Patient Training Is Vital for Achieving Positive Outcomes

The aforementioned study also indicated that a staggering one-third of patients do not receive any in-office training from their healthcare providers (HCPs) for their self-injectable medications. The few that do receive training lack uniform instruction, as training methods vary widely.

Moreover, HCPs often lack the skills needed to provide helpful and proper training to their patients. When training does occur, it is often curt and does not offer time for patients to practice or ask questions.

In addition, because so many HCPs and pharma companies refer to the self-injection process as “easy”, patients are often reluctant to express their apprehensions and anxieties, and abstain from seeking additional support altogether.

For patients with chronic conditions such as Crohn’s disease and rheumatoid arthritis— among others that require self-injectable therapies— it has become clear that proper onboarding practices are imperative when trying to improve patient adherence to self-administrated medicines. By developing robust solutions like AdhereIT®, Noble can empower patients to become more confident in their self-injecting, which enables them to stay adherent to their medication.

AdhereIT® is a connected, user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to self-administer their medication. It works with either an autoinjector training device or an actual drug delivery device to detect the beginning and end of a patient’s injection session. It is an indispensable tool during clinical trials, as it helps to lower development costs while putting knowledge and power back in patient and clinician hands.

AdhereIT® reflects Noble’s deep understanding of patient anxieties regarding self-injectables and the challenges that stem from the lack of a proper training and onboarding process.

AdhereIT® addresses potential variables through innovative solutions such as:

  • Flexible Hardware Design – accommodates most autoinjectors on the market by offering two design options:
    • 360 Base – for a two-handed injection process
    • 360 Clip – for a one-handed injection process
  • Flexible App Capabilities – accommodates various needs for brands in clinical and commercial applications while meeting the needs of various disease states and conditions
  • Quick and Accurate Data Collection – allows for easy tracking and monitoring of therapeutic treatments via patient dashboards including time of injection, symptoms and more
  • Patient Education – improves the self-injection experience by mitigating patient anxieties

Proper practice of the self-injection process is a vital patient tool. Noble combines its knowledge and understanding of patient needs and anxieties regarding the self-injection process with its design and engineering expertise to develop and commercialize training devices that closely mimic the feel, force and function of the actual drug delivery device. This allows patients to practice the self-injection process with a reusable and resettable device that can help increase their confidence and adherence to self-administered drug therapies.

Noble’s robust training and onboarding solutions reduce negative transfer to help improve the efficacy of self-administered biologics and increase patient adherence.

Noble Speaks Patient®

In an effort to better meet the needs of our pharma clients and the patients that we serve, Noble has expanded its range of products and services to include training device Instructions for Use (IFUs), product launch strategy programs and training devices. Noble also works with pharma companies in the development of patient training videos— in doing so, Noble can help brands optimize their performance while helping patients learn how to properly self-administer their medications.

To learn more about how Noble’s training, onboarding and digital health solutions are increasing positive outcomes for HCPs and their patients, visit gonoble.com.

1 “The current paradigm for biologic initiation: a confirmatory quantitative analysis of self-injection training practices” published May 7, 2022, by James Hawthorne, Expert Opinion on Drug Delivery

Sponsored content by Noble

Filed Under: Sponsored Content Tagged With: noble

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS